Trial Profile
The open-label extension study of NS-304 in patients with chronic thromboembolic pulmonary hypertension (CTEPH) who completed the exploratory evaluation study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2022
Price :
$35
*
At a glance
- Drugs Selexipag (Primary)
- Indications Pulmonary hypertension
- Focus Adverse reactions
- Sponsors Nippon Shinyaku
- 06 Jun 2016 New trial record